Lupus Science and Medicine Podcast

All Episodes (42)

From new to old

From new to old From old to new

1. 

   1. Managing Lupus Nephritis: Importance of Immunosuppression and Mitigation of Tissue Fibrosis

   Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Ana Malvar and Brad Rovin. They discuss using repeat tissue biopsies to understand progression of lupus nephritis over time. They offer conjecture that both immunosuppression as well as mitigation of tissue fibrosis, resulting from inflammatory resolution, are needed in order to preserve kidney function and prevent progression to kidney failure. Read the related article - http://dx.doi.org/10.1136/lupus-2023-000932

   Oct 02,2023 23:27
2. 

   2. Testing a new measure of lupus improvement that encompasses the patients’ perspectives and doctors’ evaluations

   Dr. Anna Wolska from the Lupus Foundation of America interviews Drs. Anca Askanase and Joan Merrill, the developers of the LFA-REAL tool. Together, they discuss the importance of using a tool like LFA-REAL to understand how clinician and patient reported outcomes are essential for understanding efficacy and effectiveness of experimental therapeutics developed to treat people living with lupus. Read the article: http://dx.doi.org/10.1136/lupus-2022-000875

   Sep 04,2023 18:05
3. 

   3. Understanding Lupus: Exploring the Differences between Type 1 and Type 2 Symptoms

   Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Amrie Grammer and Dr. Peter Lipsky from AMPEL BioSolutions. Together they describe the molecular endotypes of Type 1 and Type 2 Systemic Lupus Erythematosus. This episode uncovers the distinct molecular profiles of these SLE types and paves the way for personalized treatment approaches based on these classifications. Link to published paper: https://lupus.bmj.com/content/10/1/e000861

   Aug 07,2023 20:25
4. 

   4. Unpacking Lupus Treatment: How Quickly Does Anifrolumab Start Working? Insights from TULIP Trials

   Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Ian Bruce, from the University of Manchester in the UK. Dr Bruce discusses the time to onset of clinical response to Anifrolumab in patients with Systemic Lupus Erythematosus. The episode delves into pooled data from two significant Phase III trials, TULIP-1 and TULIP-2, offering listeners a deep understanding of the effectiveness and timeline of Anifrolumab treatment. Read the article: http://dx.doi.org/10.1136/lupus-2022-00076

   Jul 03,2023 14:42
5. 

   5. Biomarker reduction indicates treatment response to Belimumab

   Dr. Anna Wolska from the Lupus Foundation of America interviews Dr. Andrea Fava from Johns Hopkins University about Belimumab treatment in lupus nephritis. Dr Fava elucidates on the correlation between the decrease in urinary CD163 levels and the response to Belimumab treatment in Lupus Nephritis trials. The conversation provides important insights into the efficacy of this treatment option and potential biomarker use for personalized and precision medicine in the future. Read the article: dx.do

   May 24,2023 14:35
6. 

   6. Mesenchymal stromal cells: a potential new SLE treatment option?

   Duane Peters from the Lupus Foundation of America interviews Dr Gary Gilkeson from the Medical University of South Carolina about a phase I trial into the use of mesenchymal stromal cells (MSC) in refractory lupus patients in the USA, following impressive results of clinical improvement resulting from this therapy in China. The trial indicated that infusions of MSCs derived from the umbilical cord are safe and may be effective in treating mild to moderate systemic lupus erythematosus, with minim

   Aug 02,2022 17:58
7. 

   7. Using patient registries to estimate SLE incidence rate in the USA

   Duane Peters from the Lupus Foundation of America interviews Dr Peter Izmirly from New York University and Dr Elizabeth Ferucci from the Alaska Native Tribal Health Consortium, both in the USA. They discuss the establishment of a network of population-based lupus patient registries in the USA and how these have been used to estimate the incidence rate of systemic lupus erythematosus using standardised data stratified by sex, race and ethnicity.Access the article: https://lupus.bmj.com/content/8/

   May 26,2022 16:53
8. 

   8. Defining remission in systemic lupus erythematosus

   Duane Peters from the Lupus Foundation of America interviews Professor Ronald van Vollenhoven from the Amsterdam University Medical Centers in the Netherlands and Dr Cynthia Aranow from the Feinstein Institute for Medical Research in New York, USA. They discuss the efforts of the DORIS international task force to agree on a single definition of remission in systemic lupus erythematosus, which they hope will ensure that clinicians, patients and researchers in the field are all working towards the

   May 26,2022 19:22
9. 

   9. What’s the relationship between self-efficacy and quality of life in SLE patients?

   Duane Peters from the Lupus Foundation of America talks to Dr Cristina Drenkard from Emory University and Dr Teresa Brady from Clarity Consulting and Communications, both based in Atlanta, USA. They discuss their paper on the relationship between levels of self-efficacy and health behaviours and outcomes in black women with SLE. Their study specifically evaluated the associations between age, educational level and depression in SLE patients and the degree of pain and fatigue they experienced. Th

   Apr 28,2022 20:20
10. 

    10. Challenging but achievable: reaching Low Lupus Disease Activity State (LLDAS) in childhood-onset SLE

    Duane Peters from the Lupus Foundation of America talks to Dr Sylvia Kamphuis and Dr Javad Wahadat from the Erasmus Medical Center in Rotterdam in the Netherlands about aiming for a Low Lupus Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE). They outline the difference between LLDAS and clinical remission (CR), and discuss how LLDAS may be a more achievable target for patients than CR that nevertheless still brings significant clinical benefits in terms of decre

    Apr 06,2022 20:12
11. 

    11. Could a high fiber diet positively impact the gut microbiome of SLE patients?

    Duane Peters from the Lupus Foundation of America interviews Professor Iryna Kulyk from Indiana University in the USA and Professor Martin Kriegel from the University of Münster in Germany and Yale University in the USA. They discuss their study, presented at the Lupus 21st Century conference in September 2021, on the influence of the consumption of resistant starch (a type of dietary fiber) on the composition of the gut microbiota of lupus patients.Access the abstract here: https://lupus.bmj.co

    Feb 24,2022 15:38
12. 

    12. A new biomarker for cognitive dysfunction in SLE?

    Duane Peters from the Lupus Foundation of America interviews Dr Erik Anderson and Dr Meggan Mackay from the Feinstein Institutes for Medical Research in New York in the USA. They discuss their study into imbalances in quinolinic acid and kynurenic acid levels in the brain in SLE patients, and propose that the ratio between these two metabolites could be used as a new biomarker or therapeutic target for cognitive dysfunction.Access the paper here: https://lupus.bmj.com/content/8/1/e000559

    Jan 27,2022 16:00
13. 

    13. Screening for cognitive dysfunction in SLE patients

    Duane Peters from the Lupus Foundation of America interviews Jennifer He from the University of Western Ontario in Canada about her research into using neuropsychological battery tests to determine the degree of cognitive dysfunction in lupus patients. A high degree of variability in performance across multiple tests (a high dispersion score) is associated with a higher risk of cognitive dysfunction, so this can be a useful screening/diagnostic tool.Access the paper here: https://lupus.bmj.com/c

    Dec 21,2021 16:18
14. 

    14. Highlights of ACR Convergence 2021

    Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, about the highlights of ACR Convergence 2021, which was held virtually on 3-9 November (https://www.rheumatology.org/Annual-Meeting).

    Nov 23,2021 19:00
15. 

    15. Personalised metabolite monitoring during pre-conception and pregnancy in SLE patients

    Duane Peters from the Lupus Foundation of America interviews Francisca Lambert-Fliszar and Dr Evelyne Vinet from McGill University Health Centre in Canada. They discuss monitoring 6-mercaptopurine (6-MP) metabolite levels to enable personalisation of immunosuppressive therapies prior to conception or during pregnancy, in order to most effectively and safely control the disease during this critical time. Access the paper here: https://lupus.bmj.com/content/8/1/e000519

    Nov 17,2021 18:15
16. 

    16. Can you predict lupus nephritis outcomes using machine learning models?

    Duane Peters from the Lupus Foundation of America interviews Dr Jim Oates from the Medical University of South Carolina and Ralph H. Johnson VA Medical Center in Charleston, USA. They discuss his paper on developing risk prediction models in lupus nephritis to predict outcomes at the point of diagnosis, which can be used as a decision support tool to help inform treatment strategies for patients.Access the paper here: https://lupus.bmj.com/content/8/1/e000489

    Oct 22,2021 14:03
17. 

    17. Highlights of the LUPUS & CORA 2021 joint congress

    Duane Peters from the Lupus Foundation of America interviews Dr Ronald von Vollenhoven, one of LSM's Editors-in-Chief, about the highlights of the 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) and the 6th International Congress on Controversies in Rheumatology and Autoimmunity (CORA). These events were held jointly as a virtual congress on 6-9 October 2021 (https://lupus2021.kenes.com) and showcased the best clinical, biological, and translational advances in the field

    Oct 13,2021 16:20
18. 

    18. Identifying therapeutic targets in lupus nephritis: is obtaining research tissue via biopsy safe?

    Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, one of LSM's Editors-in-Chief, and Dr Philip Carlucci from New York University in the USA, a previous recipient of the LFA's Gina M. Finzi Memorial Student Summer Fellowship. They discuss their recent paper on the safety of kidney biopsies in patients with SLE enrolled in the Accelerating Medicines Partnership in the USA, which aims to identify potential targeted treatments for lupus nephritis. Access the paper here: htt

    Oct 01,2021 20:40
19. 

    19. LSM’s first Journal Impact Factor™

    Duane Peters from the Lupus Foundation of America interviews the Lupus Science & Medicine Editors-in-Chief, Professor Jill Buyon and Professor Ronald van Vollenhoven. They discuss the recent release of LSM's first Journal Impact Factor™, explaining how it has been calculated, and what it means for the journal, its authors and readers. Access all the LSM journal metrics: https://lupus.bmj.com/pages/top-cited-articles/ and https://lupus.bmj.com/pages/about/.

    Aug 31,2021 08:26
20. 

    20. Can you conduct clinical trials on lupus patients in a home setting?

    Duane Peters from the Lupus Foundation of America interviews Dr Stephen Balevic, Dr Rachel Randell and Professor Laura Schanberg from Duke University in the USA. They discuss the advantages and challenges of designing and implementing self-controlled clinical trials for paediatric lupus patients in a home setting, based on their experience of conducting the Individual Patient Exposure and Response in Pediatric Lupus (iPERSONAL) trial. Could this be a way to effectively deliver clinical trials in

    Jul 02,2021 24:37
21. 

    21. EULAR 2021 eCongress Highlights

    Duane Peters of the Lupus Foundation of America follows up with Professor Ronald van Vollenhoven of the Amsterdam University Medical Centers to discuss the highlights of the lupus research presented at the EULAR 2021 eCongress, which was held virtually on 2-5 June 2021.EULAR Congress website: https://congress.eular.org/index.cfmEULAR 2021 abstracts: https://ard.bmj.com/content/80/Suppl_1

    Jun 08,2021 11:56
22. 

    22. Safety profile of anifrolumab in SLE patients

    Duane Peters from the Lupus Foundation of America interviews Professor Eric Morand from Monash University in Australia and Dr Raj Tummala from AstraZeneca in the USA about phase II and III trials of the human monoclonal antibody anifrolumab.Their pooled analysis of data from the MUSE, TULIP-1 and TULIP-2 trials showed that, in addition to demonstrating efficacy in adults with moderate to severe systemic lupus erythematosus (SLE), anifrolumab was generally well tolerated with an acceptable safety

    Jun 01,2021 15:06
23. 

    23. The ALPHA Project

    Duane Peters from the Lupus Foundation of America interviews Dr Susan Manzi from the Allegheny Health Network and Kathleen Arntsen from the Lupus and Allied Diseases Association, both based in the USA, about the Addressing Lupus Pillars for Health Advancement (ALPHA) Project. The ALPHA Project is the first global initiative to identify, prioritise and address top barriers in lupus impacting diagnosis, care, treatment and research. The diverse team includes lupus experts, clinicians, researchers,

    May 04,2021 18:40
24. 

    24. Lupus Academy 10th Annual Meeting Highlights

    Duane Peters of the Lupus Foundation of America follows up with Professor Ronald van Vollenhoven of the Amsterdam University Medical Centers to discuss the highlights of the 10th Annual Meeting of the Lupus Academy, which was held virtually on 16-18th April 2021. Lupus Science & Medicine is the official journal of the Lupus Academy and the abstracts from the event have been published as a supplement to the journal.Lupus Academy website: lupus-academy.org/Lupus Academy 2021 abstracts: lupus.bmj.c

    Apr 22,2021 15:30
25. 

    25. Lupus Academy Tenth Annual Meeting Preview

    Duane Peters of the Lupus Foundation of America interviews Professor Ronald van Vollenhoven of the Amsterdam University Medical Centers about the 10th Annual Meeting of the Lupus Academy, which will be held virtually from 16-18th April 2021. As well as his role as co-Editor-in-Chief of Lupus Science & Medicine, Professor van Vollenhoven is a member of the Lupus Academy Steering Committee and has been involved in the planning and development of the 10th Annual Meeting. Participation in the event

    Apr 08,2021 18:05
26. 

    26. Apolipoprotein L1 risk genotypes in Ghanaian patients

    Duane Peters from the Lupus Foundation of America interviews Dr Ashira Blazer from New York University, USA, and Dr Ida Dzifa Dey from the University of Ghana in Accra, Ghana, about the associations between apolipoprotein L1 genetic polymorphisms and disease outcomes among SLE patients in Ghana.Access the paper here: https://lupus.bmj.com/content/8/1/e000460

    Apr 06,2021 17:05
27. 

    27. Anti-Müllerian hormone in African- American women with SLE

    Duane Peters from the Lupus Foundation of America interviews Ms Meghan Angley and Dr Sam Lim from Emory University in Georgia, and Dr Megan Clowse from Duke University in North Carolina, about infertility and reproductive injustice in African-American women with systemic lupus erythematosus.Access the papers here:https://lupus.bmj.com/content/7/1/e000439https://lupus.bmj.com/content/7/1/e000455

    Mar 03,2021 17:49
28. 

    28. Efficacy and safety of rituximab biosimilar in refractory lupus

    Duane Peters from the Lupus Foundation of America interviews Dr Pintip Ngamjanyaporn and Dr Nantakarn Pongtarakulpanit from Mahidol University in Bangkok, Thailand, about their study on the short term efficacy and safety of rituximab biosimilar in refractory lupus.Access the paper here: https://lupus.bmj.com/content/7/1/e000442

    Feb 04,2021 13:25
29. 

    29. Metabolic syndrome in SLE patients

    Duane Peters from the Lupus Foundation of America interviews Dr Diane Apostolopoulos and Dr Eric Morand from Monash Health in Australia about their study into the prevalence of metabolic syndrome in patients with SLE and the potential associations between the use of glucocorticoids and specific cardiovascular risk factors.Access the paper here: https://lupus.bmj.com/content/7/1/e000436

    Jan 06,2021 15:00
30. 

    30. Validating the use of LFA-REAL to measure disease severity in SLE

    Duane Peters from the Lupus Foundation of America interviews Dr Manuel Francisco Ugarte-Gil from Peru and Dr Joan Merrill and Dr Anca Askanase from the USA about their study evaluating the use of LFA-REAL clinician-reported and patient-reported outcomes in establishing disease severity in SLE.Access the paper here: https://lupus.bmj.com/content/7/1/e000419

    Dec 16,2020 19:55
31. 

    31. ANA testing in SLE and autoimmune rheumatic diseases

    Duane Peters from the Lupus Foundation of America interviews Dr May Choi and Dr Peter Schur from the Lupus Program at Brigham and Women's Hospital in Boston. They discuss the use of the ANA assay for the diagnosis and classification of systemic lupus and other autoimmune rheumatic diseases.Access the paper here: https://lupus.bmj.com/content/7/1/e000431

    Nov 30,2020 12:47
32. 

    32. Kynurenine pathway is altered in patients with SLE and associated with severe fatigue

    Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper: Kynurenine pathway is altered in patients with SLE and associated with severe fatigue.Access the paper here: http://doi.org/10.1136/lupus-2017-000254

    Sep 02,2020 12:53
33. 

    33. TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus

    Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper:TNF-alpha and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Access the paper here: http://doi.org/10.1136/lupus-2018-000260

    Aug 05,2020 16:41
34. 

    34. Lupus Science & Medicine: what makes it special?

    Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, Professor of Rheumatology at New York University School of Medicine and co-Editor-in-Chief of Lupus Science & Medicine. Dr Buyon presents an overview of the journal's strengths and unique features, the editorial review process, and why authors should consider submitting their next lupus paper to LSM.Learn more about the journal at lupus.bmj.com

    Jul 07,2020 13:09
35. 

    35. Anifrolumab effects on rash and arthritis

    Lupus Science & Medicine Associate Editor Professor Lars Ronnblom talks to Professor Joan T. Merrill from the Oklahoma Medical Research Foundation about her published paper: Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus.Access the paper here: https://lupus.bmj.com/content/5/1/e000284

    Jul 01,2020 17:15
36. 

    36. COVID-19 Impact on people with lupus

    Dr Jill Buyon, co-Editor in Chief of Lupus, Science & Medicine, explores the lessons we're learning six months into the global pandemic and the impact this is having on lupus patients, the medical landscape, and the research publishing space.

    Jun 04,2020 15:13
37. 

    37. Lupus, immunity and Covid-19 - Part 2

    In the second part of a general update on the effects of Covid-19 in lupus patients, Sara Booth, University of Cambridge, talks to Dr Anca D Askanase, MD, MPH Director, Columbia University Lupus Center Associate Professor of Medicine Columbia University College of Physicians and Surgeons.Listen to part one on your favourite podcast provider, including one of the links below:https://soundcloud.com/bmjpodcasts/immunity-for-lupus-patients-and-effects-of-covid-19-part-1Apple Podcasts:https://.com/gb

    Apr 12,2020 37:10
38. 

    38. Immunity for lupus patients and effects of Covid-19 - Part 1

    In this podcast, Sara Booth, University of Cambridge, talks to Professor Sarah Rowlands (Florey Professor of Infection and Immunity,University of Sheffield and Honorary Consultant Physician Nuffield Department of Medicine, Oxford), who specialises in infectious diseases and has a special interest in immunity to viruses.Listen to part two on your favourite podcast provider, including one of the links below:https://soundcloud.com/bmjpodcasts/lupus-immunity-and-covid-19-part-2Apple Podcasts:https:/

    Apr 08,2020 28:31
39. 

    39. Education and the latest in treatment: reporting from the Lupus Academy 2017

    An insight into the important learnings of the Lupus Academy 2017 is brought to you in this special Lupus Science & Medicine podcast.The Editor-in-Chief of the journal Ronald van Vollenhoven, a founding member of the Lupus Academy, spoke with several of the faculty and the delegates during the meeting held in Lisbon, Portugal, between the 5th and the 7th of May.The Lupus Academy is a UK-based not-for-profit organisation dedicated to providing high-quality education to medical specialists and tra

    Jun 06,2017 12:07
40. 

    40. Lupus Science and Medicine first year anniversary

    To mark the first anniversary of Lupus Science and Medicine Harriet Vickers speaks to Dr Ronald van Vollenhoven and Dr Jill Buyon about notable published papers, publishing without an impact factor and what to expect from the journal in the coming year.

    May 22,2015 13:14
41. 

    41. BMJ and the Lupus Foundation of America announce the first open access lupus scientific journal

    Sandra Raymond, president and CEO of the Lupus Foundation of America, talks about why the foundation wanted to create Lupus Science and Medicine, and what she hopes the journal will achieve.For more information on the journal, see http://journals.bmj.com/site/lupus/index.html.

    Oct 23,2013 05:06
42. 

    42. What to expect from Lupus Science and Medicine

    The Lupus Foundation of America and BMJ are joining forces to publish Lupus Science and Medicine, the first open access lupus scientific journal.Joint editor-in-chief Ronald van Vollenhoven, also head of the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institutet, discusses what readers and authors can expect from the journal.To sign up for updates about the journal, go to: http://journals.bmj.com/site/lupus/index.html

    Oct 23,2013 08:56